ICICI Direct: Healthcare Global Enterprises Update

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Signs of a strong recovery amid sharp sequential growth of 28%, 75% in revenues, Ebitda, respectively, in Q2 FY21, normalisation of OPD/IPD inflows as travel restrictions ease out point towards a better H2FY21 vis-à-vis H1 FY21.

The domestic business has already reached near pre-Covid levels on the back of strong growth seen in Tier-II/III cities.

Furthermore, revival of inter-state travel and resumption of medical tourism from neighbouring countries (like Bangladesh) is likely to reach pre-Covid levels by the end of FY21, which will further support financials.

Click on the attachment to read the full report:

ICICI Direct HCG Company Update.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Exit mobile version